Warner Pharmaceuticals (688799.SH): Subsidiary drug arginine ibuprofen obtained approval notice for marketing application

Gelonghui, May 29丨Warner Pharmaceuticals (688799.SH) announced that recently, Hunan Warner Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Chemical Ingredient Marketing Application Approval Notice” (Notice No.: 2024YS00463) of arginine ibuprofen issued by the State Drug Administration and publicized it on the China Drug Administration Drug Evaluation Center (CDE) “Registration Information Disclosure of Active Pharmaceutical Ingredients, Pharmaceutical Excipients and Pharmaceutical Packaging Materials” platform. Arginine ibuprofen is an anti-inflammatory analgesic. It is mainly suitable for the following symptoms: toothache, dysmenorrhea, pain due to trauma (for example: movement

Gelonghui FinanceMay 29 04:17 ET

Warrant Pharmaceutical's Unit Gets Nod to Market Benidipine Hydrochloride

Hunan Warrant Pharmaceutical's (SHA:688799) unit, Hunan Warrant Pharmaceutical Chiral Drug, received approval from China's National Medical Products Administration to market raw drug ingredient benidi

MT NewswiresMay 28 05:26 ET

Warner Pharmaceuticals (688799.SH): Benidipine hydrochloride API received approval notice for marketing application

Gelonghui, May 27丨Warner Pharmaceuticals (688799.SH) announced that its wholly-owned subsidiary Hunan Warner Pharmaceutical Co., Ltd. received the “Notice of Approval of the Marketing Application for Chemical Ingredients” of benidipine hydrochloride issued by the State Drug Administration and publicized it on the “Registration Information Disclosure of Active Pharmaceutical Ingredients, Pharmaceutical Excipients and Pharmaceutical Packaging Materials” platform of the China Drug Administration (CDE) Drug Evaluation Center (CDE). Benidipine hydrochloride is a calcium channel blocker, mainly used to treat essential hypertension and angina pectoris. Benidipine hydrochloride is combined with DHP binding sites in cell membrane voltage-dependent calcium channels to inhibit calcium ions

Gelonghui FinanceMay 27 05:05 ET

Warner Pharmaceuticals (688799.SH) plans to explore investment opportunities in the medical and health sector in markets such as China and Southeast Asia through funds

Warner Pharmaceuticals (688799.SH) announced that the company plans to invest no more than RMB 40 million to pledge Hainan Heyi...

Zhitong FinanceMay 23 05:36 ET

Warner Pharmaceuticals (688799.SH): Plans to exceed 100 million yuan to participate in the establishment of Queshan Huazi

Gelonghui, April 19丨Warner Pharmaceuticals (688799.SH) announced that in order to keep up with the trend and trend of macromolecular innovative drugs becoming mainstream drug use around the world, use the investment experience and resources of professional investment institutions to explore investment opportunities in innovative application fields related to the pharmaceutical industry, strengthen the company's capabilities in macromolecular drug research and development, and actively use external talents and capital to complete the company's new drug R&D transformation and product upgrade strategy with efficiency and low risk. The company now plans to work as a limited partner, Beijing Qushan Investment Management Co., Ltd., Hunan Jinyang Investment Group The limited company and other partners signed the “”

Gelonghui FinanceApr 19 08:07 ET

Warner Pharmaceuticals (688799.SH): Plans to build a “Green Intelligent Manufacturing Base (Phase I) with an annual output of 3,000 tons of high-end APIs and intermediates for no more than 650 million yuan

Gelonghui, April 19 | Warner Pharmaceuticals (688799.SH) announced that based on the strategic development plan, the company plans to invest no more than 650 million yuan to build the “Green Intelligent Manufacturing Base (Phase I) Construction Project with an annual output of 3,000 tons of high-end APIs and intermediates” through Zhigen Pharmaceutical's investment of no more than 650 million yuan. After the construction of the project is completed, it will further expand the production scale of the company's high-end APIs and intermediates, enhance the company's green and intelligent manufacturing capabilities, consolidate the company's ability to integrate raw materials and formulations, lay the foundation for the domestic and international industrialization layout of the company's high-end APIs and intermediate products, and enhance the company's industrial support and profitability

Gelonghui FinanceApr 19 08:05 ET